Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease

PartnershipSGK1 InhibitorPositive

AI Analysis

Summary

Thryv Therapeutics entered into an exclusive worldwide licensing agreement with CSIC and Universidad Autónoma de Madrid for a novel SGK1 inhibitor scaffold with potential applications in neurodegenerative and cardiovascular diseases, including Parkinson's and Alzheimer's disease.

Importance:6/10

Sentiment:

0.60

licensingSGK1 inhibitorneurodegenerative diseaseParkinson's diseaseAlzheimer's diseasecardiovascularplatform expansion

Related Companies

$INTI

Read the original article

Published by PR Newswire Biotech on September 3, 2026 8:23 PM

Read Original